M&A Deal Summary |
|
|---|---|
| Date | 2025-01-17 |
| Target | WuXi AppTec - Medical Device Testing Operations |
| Sector | Life Science |
| Buyer(s) | NAMSA |
| Sellers(s) | WuXi AppTec |
| Deal Type | Divestiture |
SEARCH BY
NAMSA is a medical research organization providing expert regulatory, laboratory, clinical, and compliance services to medical device and healthcare product manufacturers. NAMSA was established in 1967 and is based in Northwood, Ohio.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 10 |
| Sector: Life Science M&A | 7 of 7 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Minnesota M&A | 3 of 3 |
| Country: United States M&A | 6 of 6 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-07-18 |
CRI
Munich, Germany CRI is a research institute provide the European MedTech market complete clinical research solutions to accelerate scientific outcomes to their clients. CRI was founded in 2011 and is based in Munich, Germany. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 37,832 |
| Revenue | 39.2B CNY (2024) |
WuXi AppTec is a provider of pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec was founded in 2000 and is based in Shanghai, China.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Minnesota M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-25 |
WuXi AppTec - Advanced Therapies
Shanghai, China WuXi AppTec's Advanced Therapies offers customers a complete cell therapy outsourcing solution, including viral vector manufacturing, cell therapy process development and manufacturing, and biosafety testing. |
Sell | - |
